Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving Osimertinib

Part of paid clinical trials in Durham, North Carolina.

Sponsor
Duke University
Study ID
NCT04099836
Phase
PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to investigate the safety and efficacy of giving atezolizumab combined with bevacizumab in patients with stage 4 epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) whose cancer has gotten worse while receiving osimertinib.

Key Dates

Start date
Jul 9, 2020
Status verified
Dec 2023
Primary completion
Nov 13, 2022
Completion
Jun 15, 2023

Study Design

Enrollment
7 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: atezolizumab and bevacizumab
    Atezolizumab 1200 mg IV every 3 weeks and bevacizumab 15 mg/kg IV every 3 weeks (1 cycle=3 weeks)

Primary Outcome Measure

Objective Response Assessed by the Investigator Using RECIST 1.1 [ Time Frame: Up to 2 years ]

Locations (1)

FacilityCityStateZIPSite coordinators
Duke University Medical CenterDurhamNorth Carolina27710-

Find similar trials in Durham, NC

By condition
Lung cancer
By specialty
OncologyLung oncologyLung disease
By research site
Duke University Medical Center· Durham, NC

Related Studies